In today's rapidly-changing marketplace, drug and device companies of all sizes are realizing that a product’s time to market––and resilience once there––depends in large part on developing and executing effective regulatory and quality assurance strategies.

Investors are increasingly expecting streamlined, effective production processes that minimize rework, making quality absolutely essential. This, in addition to the rise in outsourced manufacturing forces manufacturers to comply with complex set of regulations––again underscoring the need for quality across the board.

Continue Reading

The video below is a sample taken from our webinar, The Complete Guide to Root Cause Analysis & CAPA, available free and on-demand here.

The FDA Group's Larry Stevens discusses strategies for determining when Corrective and Preventative Action (CAPA) is appropriate. See transcript below.

Continue Reading